An orphan drug is a medicinal agent that has been created exclusively to treat an exceptional medical condition, the ailment itself being denoted to as an orphan disease. An orphan disease affects a tiny percentage of the populace. Most of the rare illnesses are genetic, and thus are existent throughout the individual's entire life, even if the symptoms do not appear straightaway.

The Global Orphan Drugs Market was worth $113.99 billion in 2016 and estimated to be growing at a CAGR of 7.86%, to reach $166.40 billion by 2021.

Browse market data tables and in-depth TOC of the Global Orphan Drugs Market to 2021 @
http://www.marketdataforecast.com/market-reports/global-orphan-drugs-market-1676/

The growth of the Global Orphan Drugs Market is mainly driven by factors such as extended market exclusivity, rise in cognizance for prompt diagnosis, and improving healthcare infrastructure in developing countries. Moreover, government enticements in the form of endowments, tax credits, and fees waivers are the other major factors boosting the growth of the market. However, factors such as costly procedures & high initial investment, regulatory obstacles and clinical studies hurdles are hindering the growth of the market.
The Global Orphan Drugs market is segmented based on Type and Therapeutic. The market for Orphan Drugs, on the basis of Type is segmented into Biological and Non Biological. Non Biological Orphan Drugs lead the global market, on the basis of type with more than 60% of the market share. On the basis of Therapeutic, the global Orphan Drugs market is segmented into Haematology, Neurology, Oncology, and Others. On the basis of Therapeutics, Neurology accounts for almost 40% of the entire global market share.

Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/global-orphan-drugs-market-1676/request-sample

The market has also been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. U.S accounted for the largest share in the global Orphan Drugs market in 2015, as it spends nearly 20% of its GDP on health. The global market outlook is projected to be positive as more and more governments are adopting policies to encourage this sector, especially in the developing countries.

Presently, the market for orphan drugs represents only about 6% of the complete pharmaceutical market. An extremely conducive environment currently prevails for the growth of the orphan drugs market, thereby encouraging the entry of more companies into the market. The major companies dominating the global Orphan Drugs market are Novartis, GlaxoSmithKline, Roche, Alexion, Sanofi, Bristol Myers Squibb, Pfizer, Vertex, Celgene, and Merck.

Inquire before buying: http://www.marketdataforecast.com/market-reports/global-orphan-drugs-market-1676/inquire

About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.

Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: [email protected]
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases